FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068192272> ?p ?o ?g. }

• W2068192272 endingPage "46190" @default.
• W2068192272 startingPage "46184" @default.
• W2068192272 abstract "Ceramide levels are strongly increased by stimulation of renal mesangial cells with nitric oxide (NO). This effect was shown previously to be due to a dual action of NO, comprising an activation of sphingomyelinases and an inhibition of ceramidase activity. In this study we show that the NO-triggered inhibition of neutral ceramidase activity is paralleled by a down-regulation at the protein level. A complete loss of neutral ceramidase protein is obtained after 24 h of stimulation. Whereas the selective proteasome inhibitor lactacystin blocked NO-evoked ceramidase degradation, several caspase inhibitors were ineffective. Moreover, the NO-induced degradation is reversed by the protein kinase C (PKC) activator, 12-O-tetradecanoylphorbol-13-acetate (TPA), and also by the physiological PKC activators platelet-derived growth factor-BB (PDGF), angiotensin II and ATP, resulting in a normalization of neutral ceramidase protein as well as activity. In vivophosphorylation studies using 32Pi-labeled mesangial cells revealed that TPA, PDGF, angiotensin II, and ATP trigger an increased phosphorylation of the neutral ceramidase, which is blocked by the broad spectrum PKC inhibitor Ro-31 8220 but not by CGP 41251, which has a preferential action on Ca2+-dependent isoforms, thus suggesting the involvement of a Ca2+-independent PKC isoform. In vitro phosphorylation assays using recombinant PKC isoenzymes and neutral ceramidase immunoprecipitated from unstimulated mesangial cells show that particularly the PKC-δ isoform and to a lesser extent the PKC-α isoform are efficient in directly phosphorylating neutral ceramidase. In summary, our data show that NO is able to induce degradation of neutral ceramidase, thereby promoting accumulation of ceramide in the cell. This effect is reversed by PKC activation, most probably by the PKC-δ isoenzyme, which can directly phosphorylate and thereby prevent neutral ceramidase degradation. These novel regulatory interactions will provide therapeutically valuable information to target neutral ceramidase stability and subsequent ceramide accumulation. Ceramide levels are strongly increased by stimulation of renal mesangial cells with nitric oxide (NO). This effect was shown previously to be due to a dual action of NO, comprising an activation of sphingomyelinases and an inhibition of ceramidase activity. In this study we show that the NO-triggered inhibition of neutral ceramidase activity is paralleled by a down-regulation at the protein level. A complete loss of neutral ceramidase protein is obtained after 24 h of stimulation. Whereas the selective proteasome inhibitor lactacystin blocked NO-evoked ceramidase degradation, several caspase inhibitors were ineffective. Moreover, the NO-induced degradation is reversed by the protein kinase C (PKC) activator, 12-O-tetradecanoylphorbol-13-acetate (TPA), and also by the physiological PKC activators platelet-derived growth factor-BB (PDGF), angiotensin II and ATP, resulting in a normalization of neutral ceramidase protein as well as activity. In vivophosphorylation studies using 32Pi-labeled mesangial cells revealed that TPA, PDGF, angiotensin II, and ATP trigger an increased phosphorylation of the neutral ceramidase, which is blocked by the broad spectrum PKC inhibitor Ro-31 8220 but not by CGP 41251, which has a preferential action on Ca2+-dependent isoforms, thus suggesting the involvement of a Ca2+-independent PKC isoform. In vitro phosphorylation assays using recombinant PKC isoenzymes and neutral ceramidase immunoprecipitated from unstimulated mesangial cells show that particularly the PKC-δ isoform and to a lesser extent the PKC-α isoform are efficient in directly phosphorylating neutral ceramidase. In summary, our data show that NO is able to induce degradation of neutral ceramidase, thereby promoting accumulation of ceramide in the cell. This effect is reversed by PKC activation, most probably by the PKC-δ isoenzyme, which can directly phosphorylate and thereby prevent neutral ceramidase degradation. These novel regulatory interactions will provide therapeutically valuable information to target neutral ceramidase stability and subsequent ceramide accumulation. Sphingolipids exert important roles as signaling molecules under various physiological and pathophysiological conditions (1Riboni L. Viani P. Bassi R. Prinetti A. Tettamanti G. Prog. Lipid Res. 1997; 36: 153-195Crossref PubMed Scopus (189) Google Scholar, 2Perry D.K. Hannun Y.A. Biochim. Biophys. Acta. 1998; 1436: 233-243Crossref PubMed Scopus (296) Google Scholar, 3Levade T. Jaffrézou J.P. Biochim. Biophys. Acta. 1999; 1438: 1-17Crossref PubMed Scopus (283) Google Scholar, 4Huwiler A. Kolter T. Pfeilschifter J. Sandhoff K. Biochim. Biophys. Acta. 2000; 1485: 63-99Crossref PubMed Scopus (378) Google Scholar). Particularly ceramide has gained special recognition due to its potential involvement in regulation of programmed cell death, cell growth arrest, and differentiation (1Riboni L. Viani P. Bassi R. Prinetti A. Tettamanti G. Prog. Lipid Res. 1997; 36: 153-195Crossref PubMed Scopus (189) Google Scholar, 2Perry D.K. Hannun Y.A. Biochim. Biophys. Acta. 1998; 1436: 233-243Crossref PubMed Scopus (296) Google Scholar, 3Levade T. Jaffrézou J.P. Biochim. Biophys. Acta. 1999; 1438: 1-17Crossref PubMed Scopus (283) Google Scholar, 4Huwiler A. Kolter T. Pfeilschifter J. Sandhoff K. Biochim. Biophys. Acta. 2000; 1485: 63-99Crossref PubMed Scopus (378) Google Scholar). The regulatory mechanisms that determine the intracellular ceramide level are still largely unknown. Most studies have focused on the ceramide-generating enzymes,i.e. the acid and neutral sphingomyelinases. However, sphingomyelinases only depict one side of the regulation of ceramide level. Ceramide degradation, which is carried out by ceramidases, depicts the other equally important regulatory part. This key role of ceramidases in determining cellular levels of ceramide, which is a prototypic proapoptotic stimulus, demands a proper understanding of the regulation of these enzymes. Besides an acidic form, which is localized in the lysosomes (5Li C.M. Hong S.B. Kopal G. He X. Linke T. Hou W.S. Koch J. Gatt S. Sandhoff K. Schuchman E.H. Genomics. 1998; 50: 267-274Crossref PubMed Scopus (96) Google Scholar), a neutral ceramidase has been identified recently and cloned (6Tani M. Okino N. Mori K. Tanigawa T. Izu H. Ito M. J. Biol. Chem. 2000; 275: 11229-11234Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar, 7Mitsutake S. Tani M. Okino N. Mori K. Ichinose S. Omori A. Iida H. Nakamura T. Ito M. J. Biol. Chem. 2001; 276: 26249-26259Abstract Full Text Full Text PDF PubMed Scopus (99) Google Scholar). It is tempting to speculate that this latter enzyme plays a central role in signal transduction and is counterbalancing ceramide generation by the sphingomyelinases. In recent years, nitric oxide (NO), 1The abbreviations used for: NO, nitric oxide; DMEM, Dulbecco's modified Eagle medium; Gadd45, growth arrest and DNA-damage-inducible gene 45; LC, liquid chromatography; MBP, myelin basic protein; MS, mass spectrometry; PDGF-BB, platelet-derived growth factor-BB; PBS, phosphate-buffered saline; PKC, protein kinase C; TPA, 12-O-tetradecanoylphorbol-13-acetate, Tricine,N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; Z, benzyloxycarbonyl; ATPγS, adenosine 5′-O-(thiotriphosphate). has become established as a diffusible universal messenger mediating cell-cell communication throughout the body. Excessive and uncontrolled production of NO is associated with severe diseases like septic shock, stroke, neurodegeneration, diabetes mellitus, arthritis, and other forms of acute and chronic inflammation (8Nathan C. FASEB J. 1992; 6: 3051-3064Crossref PubMed Scopus (4155) Google Scholar, 9Knowles R.G. Moncada S. Biochem. J. 1994; 298: 249-258Crossref PubMed Scopus (2505) Google Scholar, 10Krönke K.-D. Fehsel K. Kolb-Bachofen V. Biol. Chem. Hoppe-Seyler. 1995; 376: 327-343PubMed Google Scholar, 11Pfeilschifter J. Kidney Int. 1995; 51: S50-S60Google Scholar). NO-induced apoptosis has been described for a variety of cell types, but it seems to be a matter of concentration whether NO acts pro- or anti-apoptotic (for review see Refs. 12Brüne B. von Knethen A. Sandau K.B. Eur. J. Pharmacol. 1998; 351: 261-272Crossref PubMed Scopus (389) Google Scholar and 13Beck K.F. Eberhardt W. Frank S. Huwiler A. Messmer U.K. Mühl H. Pfeilschifter J. J. Exp. Biol. 1999; 202: 645-653Crossref PubMed Google Scholar). The early and rapid mechanisms of NO signaling depend primarily on post-translational modifications of pre-existing cellular proteins such as guanylate cyclase. However, the late phases that are required to accommodate the microenvironmental changes are mediated by alterations in gene expression (14Pfeilschifter J. Eberhardt W. Beck K.F. Pfluegers Arch. 2001; 442: 479-486Crossref PubMed Scopus (113) Google Scholar, 15Pfeilschifter J. Eberhardt W. Huwiler A. Eur. J. Pharmacol. 2001; 429: 279-286Crossref PubMed Scopus (48) Google Scholar). Previously, we showed (16Huwiler A. Pfeilschifter J. van den Bosch H. J. Biol. Chem. 1999; 274: 7190-7195Abstract Full Text Full Text PDF PubMed Scopus (110) Google Scholar, 17Huwiler A. Dorsch S. Briner V.A. van den Bosch H. Pfeilschifter J. Biochem. Biophys. Res. Commun. 1999; 258: 60-65Crossref PubMed Scopus (34) Google Scholar) that glomerular cells exposed to NO donors respond with a drastic increase in ceramide formation. This was due to a dual action of NO, on one side by activation of sphingomyelinases and on the other side by inhibition of ceramidase activities. In this study we investigated the mechanism by which NO reduces neutral ceramidase activity in mesangial cells. We show that NO-reduced activity of neutral ceramidase is due to proteasome-mediated degradation of the enzyme. Furthermore, we show that protein kinase C (PKC) is able to prevent degradation of the enzyme via direct phosphorylation. [32P]Orthophosphate, [γ-32P]ATP (specific activity, >5000 Ci/mmol), protein A-Sepharose CL-4B, and CNBr-activated Sepharose were from AmershamBiosciences. [14C]Ceramide (specific activity, 55 Ci/mol) was from ICN Biomedicals GmbH, Eschwege, Germany. (Z)-1-[N-[3-Aminopropyl]-N-[4-(3-aminopropylammonio)butyl]amino]-diazen-1-ium-1,2-diolate (spermine-NO) and Deta-NO were from Alexis Corp., Läufelfingen, Switzerland. ATPγS and myelin basic protein (MBP) were from Sigma. 10–20% Tris-Tricine ready gels were from Bio-Rad. 12-O-Tetradecanoylphorbol-13-acetate, Ro 318220, lactacystin, spermine, Z-VAD-FMK, and Z-DEVD-FMK were fromCalbiochem-Novabiochem. Angiotensin II was from Bachem Biochemica GmbH, Heidelberg, Germany. CGP 41251 was kindly provided by Novartis Pharma Inc., Basel, Switzerland. PDGF-BB was kindly provided by Hoffmann-La Roche. All cell culture nutrients were from Invitrogen. A synthetic peptide (ENHKDSGNHWFSTC) based on the N-terminal sequence of the murine neutral ceramidase was synthesized, coupled to keyhole limpet hemocyanin, and used to immunize rabbits. The detailed characterization is described elsewhere (18Franzen R. Pautz A. Bräutigam L. Geisslinger G. Pfeilschifter J. Huwiler A. J. Biol. Chem. 2001; 276: 35382-35389Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar). β-Actin antibody was from Santa Cruz Biotechnology Inc., Heidelberg, Germany. PKC isoenzymes were expressed and purified as described previously (19Geiges D. Meyer T. Marte B. Vanek M. Weissgerber G. Stabel S. Pfeilschifter J. Fabbro D. Huwiler A. Biochem. Pharmacol. 1997; 53: 865-875Crossref PubMed Scopus (89) Google Scholar). Rat mesangial cells were cultivated and characterized as described previously (20Pfeilschifter J. Biochem. J. 1990; 272: 469-472Crossref PubMed Scopus (90) Google Scholar). In a second step, single cells were cloned by limited dilution on 96-well plates. Clones with apparent mesangial cell morphology were characterized by positive staining for the intermediate filaments desmin and vimentin, which is considered to be specific for myogenic cells, positive staining for Thy 1.1 antigen, and negative staining for Factor VIII-related antigen and cytokeratin, excluding endothelial and epithelial contaminations, respectively. For the experiments passages 8–20 were used. Confluent mesangial cells in 60-mm diameter dishes were stimulated for the indicated times in Dulbecco's modified Eagle medium (DMEM) containing 0.1 mg/ml of fatty acid-free bovine serum albumin. To stop the reaction, the medium was removed, and the cells were washed with ice-cold phosphate-buffered saline (PBS). Cells were then scraped directly into lysis buffer (50 mmHepes, pH 7.4, 150 mm NaCl, 1.5 mmMgCl2, 1 mm EDTA, 1 mm EGTA, 10% glycerol, 1% Triton X-100, 20 mm β-glycerophosphate, 50 mm sodium fluoride, 1 mmNa3VO4, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 1 μm pepstatin A, 1 mmphenylmethylsulfonyl fluoride) and homogenized by 10 passes through a 26-gauge needle fitted to a 1-ml syringe. The homogenate was centrifuged for 10 min at 14,000 × g and the supernatant taken for protein determination. 100 μg of protein were separated on SDS-PAGE and transferred to nitrocellulose membrane. Western blot analysis was performed as described previously (21Huwiler A. Wartmann M. van den Bosch H. Pfeilschifter J. Br. J. Pharmacol. 2000; 129: 612-618Crossref PubMed Scopus (50) Google Scholar) using a polyclonal antibody against the neutral ceramidase at a dilution of 1:500 and a monoclonal antibody against β-actin at a dilution of 1:1000. Confluent mesangial cells in 30-mm diameter dishes were stimulated as indicated. Lipids were extracted (22Bligh E.G. Dyer W.J. Can. J. Biochem. Physiol. 1953; 37: 911-917Crossref Scopus (42831) Google Scholar), and ceramide was quantitated by liquid chromatography (LC)/MS/MS spectrometry exactly as described previously (18Franzen R. Pautz A. Bräutigam L. Geisslinger G. Pfeilschifter J. Huwiler A. J. Biol. Chem. 2001; 276: 35382-35389Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar). Confluent mesangial cells were stimulated as described above and homogenized in lysis buffer containing 50 mm Tris, pH 7.5, 0,5% Triton X-100, 5 mm MgCl2,1 mm EDTA, 5 mmd-galactonic acid γ-lactone for the neutral ceramidase. Activity assays were performed according to Mitsutake et al. (23Mitsutake S. Kita K. Okino N. Ito M. Anal. Biochem. 1997; 247: 52-57Crossref PubMed Scopus (46) Google Scholar) with some modifications as described previously (16Huwiler A. Pfeilschifter J. van den Bosch H. J. Biol. Chem. 1999; 274: 7190-7195Abstract Full Text Full Text PDF PubMed Scopus (110) Google Scholar, 18Franzen R. Pautz A. Bräutigam L. Geisslinger G. Pfeilschifter J. Huwiler A. J. Biol. Chem. 2001; 276: 35382-35389Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar). Confluent mesangial cells in 100-mm diameter dishes were washed twice with PBS and incubated for 48 h in DMEM containing 0.1 mg of bovine serum albumin/ml. The cells were washed three times with phosphate-free DMEM in order to remove all phosphate. Afterwards, the cells were metabolically labeled for 4 h with [32P]orthophosphate (0.5 mCi/plate). After labeling, cells were stimulated at 37 °C for the indicated times with various agents. To stop the reaction, the medium was removed, and the cells were washed twice with ice-cold buffer containing 20 mmTris, pH 7.5, 150 mm NaCl. Cells were then scraped directly into 1.0 ml of ice-cold lysis buffer and homogenized by 10 passes through a 26-gauge needle fitted to a 1-ml syringe. The homogenate was centrifuged for 15 min at 14,000 × g, and the supernatant was taken for immunoprecipitation. The supernatants (containing 2.5 × 106 cpm of labeled proteins) were incubated overnight at 4 °C with a polyclonal antiserum against the neutral ceramidase at a dilution of 1:100 and 5% fetal calf serum in lysis buffer. Then 100 μl of a 50% slurry of protein A-Sepharose CL-4B in PBS was added, and the mixture was rotated for 1 h at room temperature. After centrifugation for 5 min at 3000 × g, immunocomplexes were washed 3 times with a low salt buffer (50 mm Tris-HCl, pH 7.5, 150 mmNaCl, 0.2% Triton X-100, 2 mm EDTA, 2 mm EGTA, 0.1% SDS), 3 times with a high salt buffer (50 mmTris-HCl, pH 7.5, 500 mm NaCl, 0.2% Triton X-100, 2 mm EDTA, 2 mm EGTA, 0.1% SDS), and once with 10 mm Tris. Pellets were boiled for 5 min in Laemmli dissociation buffer and subjected to SDS-PAGE. After fixing in 25% isopropyl alcohol, 10% acetic acid, the gels were dried and exposed to an Imaging System (Fuji). Cell lysate of unstimulated mesangial cells was used for immunoprecipitation of the neutral ceramidase with a polyclonal antiserum at a dilution of 1:100 as described above. The immunocomplexes were tested for direct phosphorylation by using 1 μg of recombinant PKC isoenzymes (19Geiges D. Meyer T. Marte B. Vanek M. Weissgerber G. Stabel S. Pfeilschifter J. Fabbro D. Huwiler A. Biochem. Pharmacol. 1997; 53: 865-875Crossref PubMed Scopus (89) Google Scholar) in the presence or absence of calcium. The beads were incubated with 1 μg of the partially purified enzymes in a total volume of 40 μl containing 20 mm Tris-HCl, pH 7.4, 10 mmMgCl2, 100 μm Na2ATP, 8 μCi of [γ-32P]ATP, 250 μg/ml phosphatidylserine, 25 μg/ml diolein, 1 μm TPA, and either 100 μmCaCl2 or 100 μm EDTA for 15 min at 32 °C. To show the activities of the PKC isoenzymes, 5 μg of MBP, a well known substrate for PKC (19Geiges D. Meyer T. Marte B. Vanek M. Weissgerber G. Stabel S. Pfeilschifter J. Fabbro D. Huwiler A. Biochem. Pharmacol. 1997; 53: 865-875Crossref PubMed Scopus (89) Google Scholar), was included. Thereafter, SDS buffer was added to stop the reaction, and the samples were separated on an 8% SDS-PAGE for neutral ceramidase and 13% for MBP. Phosphorylated bands corresponding to neutral ceramidase were analyzed on an Imaging system (Fuji). 32P-Phosphorylated neutral ceramidase that was affinity-purified on an anti-ceramidase-Sepharose column was incubated with or without trypsin (100 μg/ml) in a final volume of 50 μl for 3 h at 37 °C. Thereafter, undigested samples were separated on a Tris-glycine SDS-PAGE (7% acrylamide gel), and trypsin-digested samples were separated on a Tris-Tricine SDS-PAGE (10–20% acrylamide gel). Phosphorylated bands were analyzed on an Imaging system. Statistical analysis was performed by one-way analysis of variance. For multiple comparisons with the same control group, the limit of significance was divided by the number of comparisons according to Bonferroni. Previously, we have shown (16Huwiler A. Pfeilschifter J. van den Bosch H. J. Biol. Chem. 1999; 274: 7190-7195Abstract Full Text Full Text PDF PubMed Scopus (110) Google Scholar) that high levels of nitric oxide caused an increased ceramide formation with subsequent apoptosis of mesangial cells which was due to enhanced sphingomyelinase activity and reduced ceramidase activity. We have now extended these studies and investigated the mechanism by which NO inhibits ceramidase activity. Stimulation of renal mesangial cells with the nitric oxide donor spermine-NO leads to a delayed and time-dependent reduction of neutral ceramidase activity (Fig. 1 A) with a first significant effect after 8 h of treatment. This reduction of activity is paralleled by a decrease of neutral ceramidase protein amount as shown by a Western blot analysis (Fig. 1 B). The effect on neutral ceramidase activity (Fig.2 A) and protein level (Fig.2 B) occurs in a concentration-dependent manner. A maximal reduction to ∼60% of control level is obtained with 0.3 mm spermine-NO, which is not further reduced by increasing the concentration of the NO donor. Interestingly, the protein level of neutral ceramidase is almost completely reduced at 0.3 mmof NO. The total amount of protein was not changed upon NO treatment as shown by staining for the housekeeping enzyme β-actin (Fig.1 B and 2 B, lower panels). To verify that the observed effect of spermine-NO is indeed mediated by released NO and not by an unspecific effect, spermine was used as a control substance. As seen in Fig. 2 C, spermine has no effect on neutral ceramidase protein levels nor on activity (data not shown). Furthermore, Deta-NO, another NO donor which possesses a much longer half-life than spermine-NO, shows the same effect on ceramidase protein degradation (Fig. 2 C).Figure 2Concentration-dependent effect of spermine-NO on neutral ceramidase activity (A) and protein level (B) in rat mesangial cells. Quiescent rat mesangial cells were stimulated for 24 h with the indicated concentrations of spermine-NO (SP-NO; in mm) (A and B); spermine (SP; 0.5 mm) (C) or DETA-NO (0.5 mm) (C). Thereafter, cell lysates containing 100 μg of protein were taken for a neutral ceramidase activity assay (A) or SDS-PAGE (7% acrylamide gel) and subsequent Western blot analysis (B andC) as described under “Experimental Procedures.” The generated [14C]sphingosine was separated on thin layer chromatography and evaluated on a Imaging System (Fuji). Data inA are expressed as % of control values and are means ± S.D. (n = 3–4). Neutral ceramidase activity in control cells was 20.8 ± 3.0 pmol/mg/h. *, p < 0.05; **, p < 0.01, statistically significant difference compared with the unstimulated control. Data in Bare representative of three independent experiments giving similar results.View Large Image Figure ViewerDownload (PPT) When mesangial cells were exposed to NO donors in the presence of phorbol esters which directly activate PKC, both ceramide accumulation and DNA fragmentation were completely blocked (16Huwiler A. Pfeilschifter J. van den Bosch H. J. Biol. Chem. 1999; 274: 7190-7195Abstract Full Text Full Text PDF PubMed Scopus (110) Google Scholar). We therefore investigated the effect of PKC on the NO-induced down-regulation of neutral ceramidase. Treatment of mesangial cells with spermine-NO in the presence of TPA dose-dependently reversed the inhibitory action of NO on neutral ceramidase activity (Fig.3 A). In parallel, the protein level of neutral ceramidase also recovered in the presence of TPA (Fig.3 B). Neither short term nor long term stimulation with TPA alone has any effect on neural ceramidase activity or protein level (data not shown). Furthermore, we tested the physiological activators of PKC, like platelet-derived growth factor (PDGF-BB), angiotensin II, and the stable ATP analog ATPγS, which all evoke phosphoinositide hydrolysis and generation of 1,2-diacylglycerol, the endogenous activator of PKC (24Pfeilschifter J. Hosang M. Cell. Signal. 1991; 3: 413-424Crossref PubMed Scopus (23) Google Scholar, 25Pfeilschifter J. FEBS Lett. 1986; 203: 262-266Crossref PubMed Scopus (29) Google Scholar, 26Pfeilschifter J. Cell. Signal. 1990; 2: 129-138Crossref PubMed Scopus (61) Google Scholar). All these substances mimicked the effect of TPA and reversed the NO-mediated inhibition of neutral ceramidase activity (Fig. 4 A), as well as neutral ceramidase protein level (Fig. 4 B). Consistent with the observed increase of neutral ceramidase protein by all PKC activators, we found a decrease of NO-induced ceramide formation by these substances in intact mesangial cells when performing mass spectrometry of extracted lipids (Fig. 4 C). To investigate how NO down-regulates the protein amount of neutral ceramidase, we used the protein synthesis inhibitor cycloheximide (27Ch'ih J.J. Faulkner L.S. Devin T.M. Biochem. Pharmacol. 1979; 28: 2404-2407Crossref PubMed Scopus (4) Google Scholar). As seen in Fig.5 A, the presence of cycloheximide does not abrogate the NO-mediated reduction of neutral ceramide protein nor does it affect the reversal by the PKC activators TPA, angiotensin II, or ATPγS, thus suggesting that NO modulates the degradation of neutral ceramidase rather than itsde novo synthesis. To investigate whether one of the caspases is responsible for the NO-induced degradation of neutral ceramidase, the caspase family inhibitor Z-VAD-FMK as well as the specific caspase-3 inhibitor Z-DEVD-FMK were tested. However, none of these two inhibitors is able to block NO-induced enzyme degradation at the recommended concentration of 2 μm (data not shown). In contrast, the highly selective proteasome inhibitor lactacystin inhibited the NO-induced degradation of neutral ceramidase (Fig.5 B). To study whether PKC exerts its effect on neutral ceramidase via phosphorylation of the enzyme either directly or indirectly we performed in vivo phosphorylation assays. Mesangial cells were labeled with [32P]orthophosphate before stimulation. Thereafter, neutral ceramidase was immunoprecipitated, and incorporated 32P was analyzed. As seen in Fig. 6 A, stimulation of cells for 10 min with TPA causes a dose-dependent increase of phosphorylated neutral ceramidase. Similarly, PDGF-BB (Fig.6 A) and angiotensin II (Fig. 6 B) also induce phosphorylation of the enzyme. The TPA-induced phosphorylation is inhibited by the potent PKC inhibitor Ro 318220 (28Wilkinson S.E. Parker P.J. Nixon J.S. Biochem. J. 1993; 294: 335-337Crossref PubMed Scopus (495) Google Scholar) but not by CGP 41251 (29Meyer T. Regenass U. Fabbro D. Alteri E. Rösel J. Müller M. Caravatti G. Matter A. Int. J. Cancer. 1989; 43: 851-856Crossref PubMed Scopus (435) Google Scholar), an inhibitor that preferentially blocks Ca2+-dependent PKC isoenzymes (30Ochsner M. Huwiler A. Fleck T. Pfeilschifter J. Eur. J. Pharmacol. Mol. Pharmacol. Sec. 1993; 245: 15-21Crossref PubMed Scopus (32) Google Scholar, 31Marte B.M. Meyer T. Stabel S. Standke G.J.R. Jaken S. Fabbro D. Hynes N.E. Cell Growth Differ. 1994; 5: 239-247PubMed Google Scholar) (Fig.7).Figure 7Effect of PKC inhibitors on TPA-induced phosphorylation of neutral ceramidase in mesangial cells. 32P-Labeled mesangial cells were preincubated for 20 min with either Ro 318220 (1 μm) or CGP 41251 (1 μm) as indicated before stimulation with TPA (in nm) for 10 min. Cells were then lysed, and neutral ceramidase was immunoprecipitated with a polyclonal antibody at a dilution of 1:100, as described under the “Experimental Procedures.” The immunoprecipitates were separated by SDS-PAGE (7% acrylamide gels) and visualized on a Imaging System (Fuji). Data are representative of two independent experiments giving similar results.View Large Image Figure ViewerDownload (PPT) Moreover, we investigated whether PKC directly phosphorylates the neutral ceramidase in an in vitro system. Neutral ceramidase was enriched by immunoprecipitating the enzyme from unstimulated mesangial cell lysates and was then incubated with recombinant PKC of the four subtypes that have been identified in mesangial cells, i.e. PKC-α, -δ, -ε, and -ζ (32Huwiler A. Fabbro D. Pfeilschifter J. Biochem. J. 1991; 279: 441-445Crossref PubMed Scopus (76) Google Scholar, 33Huwiler A. Fabbro D. Stabel S. Pfeilschifter J. FEBS Lett. 1992; 300: 259-262Crossref PubMed Scopus (59) Google Scholar, 34Huwiler A. Schulze-Lohoff E. Fabbro D. Pfeilschifter J. Exp. Nephrol. 1993; 1: 19-25PubMed Google Scholar). As seen in Fig. 8, upper panel, the PKC-δ is the most efficient isoform to phosphorylate neutral ceramidase, which appears as a double band at ∼120 kDa. PKC-α and PKC-ζ induce only minor phosphorylation of the neutral ceramidase. In contrast, PKC-ε has no effect. To verify that all PKC isoenzymes used are active enzymes, phosphorylation of MBP, which is a well accepted substrate for PKC isoenzymes (19Geiges D. Meyer T. Marte B. Vanek M. Weissgerber G. Stabel S. Pfeilschifter J. Fabbro D. Huwiler A. Biochem. Pharmacol. 1997; 53: 865-875Crossref PubMed Scopus (89) Google Scholar), is shown (Fig. 8,lower panel). We further investigated whether the phosphorylation of neutral ceramidase by PKC in vitro occurs at the same phosphorylation sites as in intact cells. For this the phosphorylation pattern of in vivo phosphorylated neutral ceramidase was compared with in vitro phosphorylated ceramidase after trypsin digestion. As seen in Fig.9 A,32P-phosphorylated ceramidase from in vivo andin vitro assays runs at 120 kDa on a 7% Tris-glycine gel system. Upon trypsin digestion, enzyme preparations are both fragmented into an identical pattern of polypeptides. By using a 10–20% gradient Tris-Tricine gel system to allow a better separation of small polypeptides, two radioactive fragments between 15 and 20 kDa can be detected (Fig. 9 B).Figure 9Phosphopeptide mapping of trypsin-digested phosphorylated neutral ceramidase. Neutral ceramidase, either purified from mesangial cells and subjected to in vitrophosphorylation by PKC-δ (A, right lane) or affinity-purified from in vivo Pi-labeled TPA-stimulated mesangial cells (A, left lane), was digested with trypsin as described under “Experimental Procedures.” Undigested control samples were separated on a Tris-glycine SDS-PAGE (7% acrylamide gel) (A), whereas trypsin-digested samples were separated on a Tris-Tricine SDS-PAGE (10–20% gradient) (B). Gels were analyzed on an Imaging system (Fuji) for radioactive fragments.View Large Image Figure ViewerDownload (PPT) Mesangial cells have been shown to respond to high amounts of NO with an increased generation of the sphingolipid molecule ceramide, which involves a dual mechanism, the activation of sphingomyelinases, and the concomitant inhibition of ceramidase activities (16Huwiler A. Pfeilschifter J. van den Bosch H. J. Biol. Chem. 1999; 274: 7190-7195Abstract Full Text Full Text PDF PubMed Scopus (110) Google Scholar). In this study, we have investigated the mechanism by which NO reduces neutral ceramidase activity. Our data clearly show that the NO-mediated reduction of neutral ceramidase activity is paralleled by a decrease of the ceramidase protein level. This suggests that either the de novo synthesis of neutral ceramidase is blocked by NO or that NO induces degradation of the enzyme. The experiments performed in the presence of the protein synthesis inhibitor cycloheximide, which does not affect the NO-triggered down-regulation nor the basal level of neutral ceramidase (Fig. 5), rather argues for an increased degradation of the enzyme. This notion is further substantiated by the observation that a specific proteasome inhibitor blocked NO-induced ceramidase degradation, whereas several caspase inhibitors were without effect. Thus ceramidase is targeted by the ubiquitin proteasome machinery in mesangial cells. Interestingly, the NO-mediated degradation of ceramidase can be reversed by PKC-activating agents, like the phorbol ester TPA, and also the physiologically important ligands PDGF, angiotensin II, and ATP. The mechanisms by which PKC prevents degradation are still unclear, but it is tempting to speculate that phosphorylation events play an important role. Phosphorylation is a well known mechanism for regulating protein stability. Thus many proteins are subjected to phosphorylation and as a consequence are degraded more rapidly, like the inhibitor of κB (35Steffan N.M. Bren G.D. Frantz B. Tocci M.J. O'Neill E.A. Paya C.V. J. Immunol. 1995; 155: 4685-4691PubMed Google Scholar), the transcription factor RelB, which is a member of the Rel/NF-κB family of transcription factors (36Marienfeld R. Berberich-Siebelt F. Berberich I. Denk A. Serfling E. Neumann M. Oncogene. 2001; 20: 8142-8147Crossref PubMed Scopus (61) Google Scholar), or the tumor suppressor protein p53 (37Chernov M.V. Bean L.J. Lerner N. Stark G.R. J. Biol. Chem. 2001; 276: 31819-31824Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar). On the contrary, phosphorylation may also stabilize certain proteins like the epidermal growth factor receptor (38Bao J. Alroy I. Waterman H. Schejter E.D. Brodie C. Gruenberg J. Yarden Y. J. Biol. Chem. 2000; 275: 26178-26186Abstract Full Text Full Text PDF PubMed Scopus (151) Google Scholar), the growth arrest and DNA damage-inducible gene gadd45 (39Leung C.H. Lam W. Zhuang W.J. Wong N.S. Yang M.S. Fong W.F. Biochem. Biophys. Res. Commun. 2001; 285: 283-288Crossref PubMed Scopus (15) Google Scholar), or the human proto-oncogene ETS-2 (40Fujiwara S. Fisher R.J. Bhat N.K. Diaz de la Espina S.M. Papas T.S. Mol. Cell. Biol. 1988; 8: 4700-4706Crossref PubMed Scopus (47) Google Scholar) and thereby lead to their accumulation. In the case of neutral ceramidase, it seems that phosphorylation of the enzyme by PKC directly or indirectly by alteration of another kinase or phosphatase activity leads to reduced protein degradation. Our data further suggest that in mesangial cells the PKC-δ isoenzyme is the most likely candidate for a direct stabilizing effect. This finding is corroborated by the fact that (i) only the broad spectrum PKC inhibitor Ro-31 8220, but not the inhibitor of the Ca2+-dependent PKC isoenzymes, CGP 41251, is able to block TPA-stimulated phosphorylation of neutral ceramidase and that (ii) recombinant PKC-δ is the most effective isoform to phosphorylate neutral ceramidase in an in vitrosystem. In accordance with our data, Leung et al. (39Leung C.H. Lam W. Zhuang W.J. Wong N.S. Yang M.S. Fong W.F. Biochem. Biophys. Res. Commun. 2001; 285: 283-288Crossref PubMed Scopus (15) Google Scholar) reported that PKC-δ plays an important role in protein stabilization of Gadd45 in A431 cells. Mechanistically, they showed that epidermal growth factor, by activating PKC-δ, decreased ubiquitination of Gadd45, an effect that was blocked by the PKC-δ-selective inhibitor rottlerin. It is tempting to speculate that PKC-δ also decreases ubiquitination of neutral ceramidase and thus stabilizes the enzyme in mesangial cells. By sequence analysis of neutral ceramidase, nine putative PKC and several casein kinase II consensus phosphorylation sites can be found in the primary sequence (7Mitsutake S. Tani M. Okino N. Mori K. Ichinose S. Omori A. Iida H. Nakamura T. Ito M. J. Biol. Chem. 2001; 276: 26249-26259Abstract Full Text Full Text PDF PubMed Scopus (99) Google Scholar). However, site-directed mutagenesis studies of these phosphorylation sites will be required in order to identify which of these putative PKC phosphorylation sites, if any, are indeed relevant for ceramidase stability. Remarkably, phosphorylation of neutral ceramidase per se, either by PKC or another kinase, seems not to be sufficient for activation, since short term stimulation with either TPA, PDGF-BB, or angiotensin II did not change the activity of the enzyme (data not shown). This contrasts to a report by Coroneos et al. (41Coroneos E. Martinez M. McKenna S. Kester M. J. Biol. Chem. 1995; 270: 23305-23309Abstract Full Text Full Text PDF PubMed Scopus (215) Google Scholar), who found that PDGF activated an alkaline ceramidase in mesangial cells. This activation was under the regulation of a tyrosine phosphatase because activity increased in the presence of vanadate. Whether this alkaline ceramidase is identical to the neutral ceramidase investigated in this study is not clear, since no biochemical characterization of the alkaline enzyme has been reported. Moreover, when we added vanadate to mesangial cells, it had no effect on neutral ceramidase activity (data not shown). One obvious cellular consequence of neutral ceramidase stabilization by PKC is a more efficient elimination of ceramide which in turn may protect the cell from the proapoptotic action of this lipid mediator. There is increasing evidence that PKC can act as a cytoprotective enzyme preventing stress-induced programmed cell death (apoptosis) in various cell types, including mesangial cells (16Huwiler A. Pfeilschifter J. van den Bosch H. J. Biol. Chem. 1999; 274: 7190-7195Abstract Full Text Full Text PDF PubMed Scopus (110) Google Scholar, 42Meinhardt G. Roth J. Totok G. Eur. J. Cell Biol. 2000; 79: 824-833Crossref PubMed Scopus (34) Google Scholar). Furthermore, Jun et al. (43Jun C.D. Oh C.D. Kwak H.J. Pae H.O. Yoo J.C. Choi B.M. Chun J.S. Park R.K. Chung H.T.J. J. Immunol. 1999; 162: 3395-3401PubMed Google Scholar) described that overexpression of PKC-βII, -δ, and -η isoenzymes protected 264.7 macrophages from nitric oxide-induced apoptosis by blocking nitric oxide-activating effects on c-Jun N-terminal kinase/stress-activated protein kinase and p38 kinase. Moreover, overexpression of PKC-α in 32D myeloid progenitor cells leads to an increased activation of the protein kinase B/Akt which promotes cell survival (44Li W. Zhang J. Flechner L. Hyun T. Yam A. Franke T.F. Pierce J.H. Oncogene. 1999; 18: 6564-6572Crossref PubMed Scopus (94) Google Scholar). Obviously, there is a cell type-specific involvement of PKC isoenzymes in cell protection. From our data, we conclude that especially the PKC-δ is a prime candidate for exerting an anti-apoptotic effect in mesangial cells via stabilizing neutral ceramidase. This fits with our previous findings and hypothesis (45Huwiler A. Pfeilschifter J. Br. J. Pharmacol. 1994; 113: 1455-1463Crossref PubMed Scopus (100) Google Scholar) that PKC-δ mediates mitogen-activated protein kinase activation in mesangial cells and promotes proliferation in response to extracellular nucleotides. In this context it is worth noting that ceramide is able to bind directly to PKC-δ in mesangial cells (46Huwiler A. Fabbro D. Pfeilschifter J. Biochemistry. 1998; 37: 14556-14562Crossref PubMed Scopus (106) Google Scholar). Such a binding leads to a decreased autophosphorylation of PKC-δ probably reflecting an inhibitory effect on the activity of the enzyme. This may constitute an intriguing positive feedback loop, with increased ceramide levels causing inhibition of PKC-δ, which in turn leads to an increased degradation of neutral ceramidase and amplified ceramide accumulation. Powerful negatively acting regulatory pathways are required to terminate amplification loops such as the one suggested here. Noteworthy, ceramide also binds to and triggers PKC-α-mediated feedback inhibition of cytokine-induced ceramide formation (46Huwiler A. Fabbro D. Pfeilschifter J. Biochemistry. 1998; 37: 14556-14562Crossref PubMed Scopus (106) Google Scholar, 47Kaszkin M. Huwiler A. Scholz K. van den Bosch H. Pfeilschifter J. FEBS Lett. 1998; 440: 163-166Crossref PubMed Scopus (23) Google Scholar, 48Peilschifter J. Huwiler A. News Physiol. Sci. 1999; 15: 11-15Google Scholar). Can these seemingly disparate results be reconciled? We suggest that ceramide acts as a negative feedback regulator to control its own synthesis in response to cytokine stimulation via PKC-α activation. But as soon as a critical threshold of activation is reached and high amounts of NO are produced by a delayed cytokine-induced expression of the inducible NO synthase, ceramide then functions as a positive feedback modulator to amplify its production via ceramidase destabilization due to inhibition of PKC-δ. This may operate in a switch-like mechanism (49Pfeilschifter J. Beck K.-F. Eberhardt W. Huwiler A. Kidney Int. 2002; 61: 809-815Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar) and initiate programmed cell death which is a common phenomenon in acute inflammation as well as resolution of disease (50Savill J. Johnson R.J. Exp. Nephrol. 1995; 3: 149-158PubMed Google Scholar). Taken together the results of this study provide evidence that NO blocks neutral ceramidase activity by inducing degradation of the enzyme and that this effect can be reversed by activating PKC, especially the δ−isoform. The neutral ceramidase may thus represent a novel attractive target to interfere with cellular stress response and to modulate programmed cell death which is a typical feature of many inflammatory diseases." @default.
• W2068192272 created "2016-06-24" @default.
• W2068192272 creator A5011479527 @default.
• W2068192272 creator A5019719249 @default.
• W2068192272 creator A5046524304 @default.
• W2068192272 creator A5074909982 @default.
• W2068192272 creator A5088322762 @default.
• W2068192272 date "2002-11-01" @default.
• W2068192272 modified "2023-09-30" @default.
• W2068192272 title "Nitric Oxide Induces Degradation of the Neutral Ceramidase in Rat Renal Mesangial Cells and Is Counterregulated by Protein Kinase C" @default.
• W2068192272 cites W1428583350 @default.
• W2068192272 cites W1481124055 @default.
• W2068192272 cites W1484441747 @default.
• W2068192272 cites W1764308599 @default.
• W2068192272 cites W1822066871 @default.
• W2068192272 cites W1834041853 @default.
• W2068192272 cites W1967453408 @default.
• W2068192272 cites W1972917887 @default.
• W2068192272 cites W1977199922 @default.
• W2068192272 cites W1978048485 @default.
• W2068192272 cites W1981412298 @default.
• W2068192272 cites W1981707898 @default.
• W2068192272 cites W2000450562 @default.
• W2068192272 cites W2004559509 @default.
• W2068192272 cites W2012274640 @default.
• W2068192272 cites W2012441935 @default.
• W2068192272 cites W2012451275 @default.
• W2068192272 cites W2012507368 @default.
• W2068192272 cites W2013298748 @default.
• W2068192272 cites W2017264655 @default.
• W2068192272 cites W2023357543 @default.
• W2068192272 cites W2023943529 @default.
• W2068192272 cites W2025338956 @default.
• W2068192272 cites W2034156463 @default.
• W2068192272 cites W2037892813 @default.
• W2068192272 cites W2040857561 @default.
• W2068192272 cites W2050613670 @default.
• W2068192272 cites W2051531396 @default.
• W2068192272 cites W2054336734 @default.
• W2068192272 cites W2055816456 @default.
• W2068192272 cites W2062402765 @default.
• W2068192272 cites W2068107818 @default.
• W2068192272 cites W2074705735 @default.
• W2068192272 cites W2089293203 @default.
• W2068192272 cites W2089433735 @default.
• W2068192272 cites W2124985194 @default.
• W2068192272 cites W2146159955 @default.
• W2068192272 cites W2210423567 @default.
• W2068192272 cites W2300552860 @default.
• W2068192272 cites W2323808050 @default.
• W2068192272 cites W2408960331 @default.
• W2068192272 doi "https://doi.org/10.1074/jbc.m204034200" @default.
• W2068192272 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12359735" @default.
• W2068192272 hasPublicationYear "2002" @default.
• W2068192272 type Work @default.
• W2068192272 sameAs 2068192272 @default.
• W2068192272 citedByCount "59" @default.
• W2068192272 countsByYear W20681922722012 @default.
• W2068192272 countsByYear W20681922722013 @default.
• W2068192272 countsByYear W20681922722014 @default.
• W2068192272 countsByYear W20681922722015 @default.
• W2068192272 countsByYear W20681922722016 @default.
• W2068192272 countsByYear W20681922722017 @default.
• W2068192272 countsByYear W20681922722019 @default.
• W2068192272 countsByYear W20681922722022 @default.
• W2068192272 countsByYear W20681922722023 @default.
• W2068192272 crossrefType "journal-article" @default.
• W2068192272 hasAuthorship W2068192272A5011479527 @default.
• W2068192272 hasAuthorship W2068192272A5019719249 @default.
• W2068192272 hasAuthorship W2068192272A5046524304 @default.
• W2068192272 hasAuthorship W2068192272A5074909982 @default.
• W2068192272 hasAuthorship W2068192272A5088322762 @default.
• W2068192272 hasBestOaLocation W20681922721 @default.
• W2068192272 hasConcept C126322002 @default.
• W2068192272 hasConcept C134018914 @default.
• W2068192272 hasConcept C178790620 @default.
• W2068192272 hasConcept C185592680 @default.
• W2068192272 hasConcept C519581460 @default.
• W2068192272 hasConcept C55493867 @default.
• W2068192272 hasConcept C71924100 @default.
• W2068192272 hasConcept C86803240 @default.
• W2068192272 hasConcept C95444343 @default.
• W2068192272 hasConceptScore W2068192272C126322002 @default.
• W2068192272 hasConceptScore W2068192272C134018914 @default.
• W2068192272 hasConceptScore W2068192272C178790620 @default.
• W2068192272 hasConceptScore W2068192272C185592680 @default.
• W2068192272 hasConceptScore W2068192272C519581460 @default.
• W2068192272 hasConceptScore W2068192272C55493867 @default.
• W2068192272 hasConceptScore W2068192272C71924100 @default.
• W2068192272 hasConceptScore W2068192272C86803240 @default.
• W2068192272 hasConceptScore W2068192272C95444343 @default.
• W2068192272 hasIssue "48" @default.
• W2068192272 hasLocation W20681922721 @default.
• W2068192272 hasOpenAccess W2068192272 @default.
• W2068192272 hasPrimaryLocation W20681922721 @default.
• W2068192272 hasRelatedWork W1966504330 @default.
• W2068192272 hasRelatedWork W1966775726 @default.
• W2068192272 hasRelatedWork W1979139803 @default.

• next